Dramatic Response After Switching MEK Inhibitors in a Patient With Refractory Mixed Histiocytosis

We report the case of a patient with progressive multisystem mixed histiocytosis associating Langerhans cell histiocytosis (LCH) and Erdheim-Chester disease (ECD) involving the bone marrow, whose lesions harbored the MAP2K1 E102-I103del. After initial improvement under the MEK inhibitor trametinib,...

Descripción completa

Detalles Bibliográficos
Autores principales: Roeser, Anais, Jouenne, Fanelie, Vercellino, Laetitia, Calvani, Julien, Goldwirt, Lauriane, Lorillon, Gwenael, Tazi, Abdellatif
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635797/
https://www.ncbi.nlm.nih.gov/pubmed/36406830
http://dx.doi.org/10.14740/jh1030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635797/
https://www.ncbi.nlm.nih.gov/pubmed/36406830
http://dx.doi.org/10.14740/jh1030

Ejemplares similares